跳至主要内容
临床试验/NCT01480336
NCT01480336已完成不适用

The Pharmacokinetics and Electrocardiographic Implications of Adjunctive Amiodarone and Ranolazine Therapy in Patients on Implantable Cardioverter Defibrillators: The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot

Hartford Hospital1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2011年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
19
试验地点
1
主要终点
Pharmacokinetic Parameter Estimates

研究概览

简要总结

The purpose of this study is to learn if combination therapy with amiodarone and ranolazine (an approved drug for chest pain) can help prevent arrhythmias.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Double (Participant, Investigator)

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with an ICD who were on a stable dose of amiodarone for the past 60 days

排除标准

  • Patients with a life expectancy of less than 6 months
  • Patients with moderate or severe hepatic impairment (Child-Pugh Classes B or C) or requiring hemodialysis.
  • Pregnancy or lactation.
  • Treatment with potent CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, indinavir, and saquinavir
  • Treatment with CYP3A inducers, including rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort.

研究组 & 干预措施

Amiodarone with Placebo

Placebo Comparator

干预措施: Amiodarone with Placebo (Drug)

Amiodarone with Ranolazine

Active Comparator

干预措施: Amiodarone Plus Ranolazine (Drug)

结局指标

主要结局

Pharmacokinetic Parameter Estimates

时间窗: 12 hours

Absorption, Peak concentration, time to peak concentration, clearance, area under the curve

次要结局

  • Electrocardiogram (ECG)(12 hours)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验